Ceftazidime
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Ceftazidime
- Pharmacist Assessment Report
- Ceftazidime: third-generation cephalosporin antibiotic → hyperamylasemia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Ceftazidime: third-generation cephalosporin antibiotic → hyperamylasemia
One-Sentence Summary
Ceftazidime is an injectable third-generation cephalosporin antibiotic that works by blocking bacterial cell wall synthesis. The TxGNN model predicts it may be relevant to hyperamylasemia, but no clinical trials and no publications were found for this prediction. This is a computational signal only and has no supporting clinical evidence so far.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hyperamylasemia |
| TxGNN Prediction Score | 0.9951 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Ceftazidime is known to be a cephalosporin that binds penicillin-binding proteins and inhibits bacterial cell wall synthesis.
No plausible antibacterial mechanism links this action to hyperamylasemia, which is an elevated level of amylase in the blood. The high score reflects a pattern found by the TxGNN model, not a biological explanation or clinical observation. The data compiled for this report contain no study that tests this link, so the prediction should be treated as a hypothesis at most.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
Health Canada records show ceftazidime as marketed, with all six single-ingredient licences currently valid. The approved indication text is not recorded in the local data.
| DIN | Product Name | Status |
|---|---|---|
| 02437848 | Ceftazidime for Injection BP | Valid |
| 00886955 | Ceftazidime for Injection, USP | Valid |
| 02437856 | Ceftazidime for Injection BP | Valid |
| 02437864 | Ceftazidime for Injection BP | Valid |
| 00886971 | Ceftazidime for Injection, USP | Valid |
Safety Considerations
- Drug Interactions: Interactions rated Moderate were flagged with amphotericin B (including its cholesteryl sulfate, lipid complex and liposomal forms), kanamycin, neomycin, streptomycin and picosulfuric acid. Several other drugs have interactions of unknown severity. The compiled data list 100 interaction records in total.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no clinical trials or publications, and no plausible mechanism links ceftazidime to hyperamylasemia. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- A mechanistic hypothesis explaining why an antibacterial agent would affect amylase levels
- Any clinical or observational data on amylase changes in patients treated with ceftazidime
- Package insert warnings and contraindications from Health Canada
- Detailed mechanism-of-action data from DrugBank
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.